-
-
-
-
-
-
-
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310
-
-
-
-
-
-
-
ProMIS Neurosciences to Participate in H.C. Wainwright & Co. 22nd Annual Investment Conference
-
22,110 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

